U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C8H11NO.C3H6O3
Molecular Weight 227.257
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHYL HYDROXY PICOLINIUM LACTATE

SMILES

CC(O)C(O)=O.CCC1=C(O)C=CC(C)=N1

InChI

InChIKey=LRUSSTVFELZALO-UHFFFAOYSA-N
InChI=1S/C8H11NO.C3H6O3/c1-3-7-8(10)5-4-6(2)9-7;1-2(4)3(5)6/h4-5,10H,3H2,1-2H3;2,4H,1H3,(H,5,6)

HIDE SMILES / InChI

Molecular Formula C3H6O3
Molecular Weight 90.0779
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula C8H11NO
Molecular Weight 137.179
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Emoxypine (ethylmethylhydroxypyridine) succinate (MEXIDOL®) is a 3-hydroxypyridine derivative which is quite similar in structure to Vitamin B6 (pyridoxine). The most important components of the mechanism of action of Mexidol® are its antioxidant and membranotropic effects, the ability to modulate functioning of receptors and membrane-bound enzymes, restore a neurotransmitter balance. Due to its mechanism of action Mexidol® has a wide range of pharmacological effects, realized on at least two levels – neuronal and vascular. It has antihypoxic, anti-ischemic, neuroprotective, nootropic, vegetotrophic, anti-stress, anxiolytic, anticonvulsant, anti-alcohol, cardioprotective, anti-atherogenic, geroprotective and other actions. Under the action of Mexidol®, it is observed an improvement in cerebral circulation and microcirculation. Emoxypine is distributed in Russia but it is widely unknown in other regions.

Originator

Curator's Comment: In early 1980s, in State Institution Research Institute of Pharmacology of RAMS, by L.D. Smirnov and V.I. Kuzmin, 2-ethyl-6-methyl-3-hydroxypyridine succinate was synthesized, and under supervision of Academician of RAMS A.V. Valdman, its pharmacological effects were found, the mechanism of action was studied, preclinical studies on toxicology and pharmacokinetics were carried out, the Mexidol® trademark was identified, the drug was registered in the USSR Ministry of Healthcare, the first clinical trials and introduction of the preparation into medical practice were carried out.

Approval Year

PubMed

PubMed

TitleDatePubMed
[Antioxidant properties of 3-oxypyridine analogues: mexidol, emoxipin, proxipin].
2001 May-Jun
[Cardioprotective effect of drugs with antioxidant activity in acute cerebral ischemia].
2001 Nov-Dec
[Effect of nootropic agents on impulse activity of cerebral cortex neurons].
2001 Nov-Dec
[Effect of mexidol on oxidative stress in cerebral variant of hypertensive crisis].
2002
[Effectiveness of mexidol in acute pancreatitis].
2002
[The effect of some medications used in the treatment of cerebrovascular diseases on free radical oxidation in the model systems].
2002
[Membrane destabilizing processes in perinatal nervous system disorders in children].
2002
[Antioxidant Mexidol premedication of patients with periodontitis during antihomotoxic therapy].
2002
[Effect of mexidol, emoxypine, and dimephosphon on electrophysiological effects of nibentan].
2002 Mar-Apr
[Therapy of postresuscitation behavioral disorders with mexidol and kyotorphin].
2002 Nov-Dec
[Combined administration of mexidol and anti-arrhythmia agents].
2002 Sep-Oct
[Mexidol-induced modification of lipid metabolism in pancreatitis].
2003 Jan-Feb
[Effect of mexidol on the course of post-traumatic epilepsy].
2003 Jul-Aug
[Pharmacological activity of mexidol in the stress-induced liver damage].
2003 May-Jun
[Emoxipin in combined pharmacological defense of the kidney from ischemia and operative stress (an experimental study)].
2003 Sep-Oct
[Efficacy of emoxypine in combined therapy for elderly patients with postinfarct cardiosclerosis and heart failure].
2004
[Use of mexidol in stomatology: results and perspectives].
2004
[Antioxidant therapy in combined treatment of postoperative intestinal paresis].
2004
[Protective effect of activators of biological oxidation in nitrite intoxication in rats].
2005
[The treatment of patients with toxic encephalopathy caused by using surrogate psychoactive manganese-containing compounds].
2005
[Effects of mexidol on the antioxidative status of patients suffering from coronary heart disease with dislipidemia].
2005
[Effects of emoxipine, reamberine and mexidol on neuropathic symptoms and a systolic function of the left ventricular myocardium in patients with diabetes mellitus and diabetic foot syndrome].
2005
[Effect of mexicor on oxidative stress in acute myocardial infarction].
2005
[Antinecrotic and antiischemic effect of mexidol and trental in ischemia of the skin graft].
2005 May
[Mexidol in treatment of children with generalized epilepsy and febrile seizures].
2005 May
The effects of Mexidol on the acquisition of food-related conditioned reflexes and synaptic ultrastructure in field CA1 of the rat hippocampus after single acoustic stimuli with ultrasonic components.
2005 May
[Metabolic effects of mexidole during cardiosurgical operations using extracorporeal circulation].
2005 May-Jun
Lymphotropic effect of mexidol in reactive fever.
2005 Oct
Activity of nitric oxide synthase and concentration of nitric oxide end metabolites in the gingiva under experimental pathological conditions.
2005 Oct
[Efficacy of the use of antioxidant preparation mexidol in comprehensive treatment of inflammatory diseases of parodontium].
2006
[The use of mexidol in urgent treatment of drug addiction].
2006
[Mexidol in combined treatment of acute pancreatitis].
2006
[Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy].
2006
[Lipid reducing and antioxidant action of mexicor in patients with diabetes mellitus type 2].
2006
[Antioxidants in complex treatment of Parkinson's disease].
2006
[Neurometabolic therapy of diabetic neuropathy].
2006
[Complex therapy of acute and exacerbated chronic nonspecific parotitis including mexidol and non-coherent infrared therapy].
2006
[The use of mexidol in psychiatric practice].
2006
[Neureprotective drugs efficiency in patients with chronic tension headaches].
2006
[Antioxidant activity of inhibitors of free radical reactions in the dressing materials for wound healing].
2006 Jan-Feb
[Antistressor and analgesic effects of mexidol, diazepam, paracetamol, and their combinations].
2006 Jul-Aug
[The efficacy of oxynicotinic acid a nd its derivatives in respect of functional activity of hepatocytes during acute toxic hepatopathy].
2006 Oct-Dec
[The effectiveness of ascorbic acid and emoxipin in treatment of infiltrative pulmonary tuberculosis].
2007
[The efficacy of complex therapy of ventricular arrhythmias with emoxipin and preductal in combination with antiarrhythmic agents].
2007
[Influence of gel Metrogil Denta and curative toothpaste Mexidol Dent activ on indices of parodontal status and lipid peroxidation in patients with chronic generalized catarrhal gingivitis].
2007
Lymphotropic effect of dimephosphon, mexidol, and ketorolac is realized via activation of the lymphangion and stimulation of lymph formation.
2007 Apr
Efficacy of neuroprotectors in patients with tension headaches.
2007 Jun
[Pharmacological correction of neuronal damage in sensomotor zone of frontal cortex under conditions of experimental cerebral blood flow pathology].
2007 Nov-Dec
[Experience with complex treatment for childhood amblyopia].
2008 Jan-Feb
Patents

Patents

Sample Use Guides

Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:13:58 UTC 2023
Edited
by admin
on Sat Dec 16 02:13:58 UTC 2023
Record UNII
84438Y4KT6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHYL HYDROXY PICOLINIUM LACTATE
INCI  
INCI  
Official Name English
3-PYRIDINOL, 2-ETHYL-6-METHYL-, 2-HYDROXYPROPANOATE (SALT)
Common Name English
PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH 2-ETHYL-6-METHYL-3-PYRIDINOL (1:1)
Common Name English
ETHYL HYDROXY PICOLINIUM LACTATE [INCI]
Common Name English
2-ETHYL-6-METHYL-3-HYDROXY PYRIDINE LACTATE
Systematic Name English
2-ETHYL-6-METHYL-3-HYDROXY PYRIDINE (±)-LACTATE
Systematic Name English
EMOXYPINE LACTATE
Common Name English
2-ETHYL-6-METHYL-3-HYDROXY PYRIDINE LACTATE, (±)-
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID601021786
Created by admin on Sat Dec 16 02:13:58 UTC 2023 , Edited by admin on Sat Dec 16 02:13:58 UTC 2023
PRIMARY
FDA UNII
84438Y4KT6
Created by admin on Sat Dec 16 02:13:58 UTC 2023 , Edited by admin on Sat Dec 16 02:13:58 UTC 2023
PRIMARY
PUBCHEM
72941769
Created by admin on Sat Dec 16 02:13:58 UTC 2023 , Edited by admin on Sat Dec 16 02:13:58 UTC 2023
PRIMARY
CAS
220610-55-9
Created by admin on Sat Dec 16 02:13:58 UTC 2023 , Edited by admin on Sat Dec 16 02:13:58 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY